Stroke is the cause of about 10% of all epilepsy and 55% of newly diagnosed seizures among the elderly. Although recent advances in acute stroke therapy have improved longevity, there has been a consequent rise in the prevalence of stroke-related epilepsy (STRE). Many clinical studies make a distinction between early (within 7 days of onset of stroke) and late (beyond 7 days of onset of stroke) seizures based on presumed pathophysiological differences. Although early seizures are thought to be the consequence of local metabolic disturbances without altered neuronal networks, late seizures are thought to occur when the brain has acquired a predisposition for seizures. Overall, STRE has a good prognosis, being well controlled by antiepileptic drugs. However, up to 25% of cases become drug resistant. STRE can also result in increased morbidity, longer hospitalization, greater disability at discharge and greater resource utilization. Additional controlled trials are needed to explore the primary and secondary prevention of STRE as well as to provide highquality evidence on efficacy and tolerability of antiepileptic drugs to guide treatment of STRE. Robust pre-clinical and clinical prediction models of STRE are also needed to develop treatments to prevent the transformation of infarcted tissue into an epileptic focus.
Introduction
Post-stroke epilepsy accounts for nearly 50% of newly diagnosed epilepsy among patients over 60 years of age. With the world population aging and the resultant increased prevalence of post-stroke survivors, the number of patients with stroke-related epilepsy (STRE) is expected to increase [1, 2] . Seizures may occur at or in close temporal association with stroke [acute symptomatic, provoked or early seizures (ESs)] or after a variable interval (several days/years) following stroke [late seizures (LSs) or STRE] [3] . According to the International League Against Epilepsy definition, seizures occurring within 7 days of onset of stroke are classified as ESs and those beyond 7 days as LSs [4] . Also, per International League Against Epilepsy, epilepsy is diagnosed by the occurrence of one unprovoked seizure and the likelihood of further seizures similar to the general recurrence (>60%) after two unprovoked seizures over the next 10 years [4] . Thus, a patient with an isolated, unprovoked poststroke seizure has structural epilepsy, as the risk of developing a subsequent unprovoked seizure is around 71.5% [5] .
Although ESs are thought to result from local metabolic disturbances that have not necessarily altered neuronal networks, LSs occur when the brain has acquired a predisposition for seizures [3] . Currently, there are no evidence-based guidelines for the medical management of STRE. Although longterm antiepileptic drug (AED) use might promote vascular endothelial dysfunction increasing the risk of atherosclerosis, key stroke prevention/treatment medications (such as thrombolytics) could promote epileptogenesis [6, 7] . In stroke survivors, persistent seizure activity could hamper post-stroke recovery and cause temporary or even permanent neurological deterioration and might be associated with poor functional outcomes [8] . This review discusses current understanding of the epidemiology, risk factors, clinical manifestations, pathogenesis, electroencephalography (EEG) features and management of STRE.
Epidemiology
The National General Practice Study of Epilepsy found that vascular disease accounted for 15% of newly diagnosed epilepsy in all participants and nearly 50% were elderly [8] . The reported incidence of stroke-related seizures varies considerably, ranging from 2% to 20% [9] [10] [11] . This variation reflects differences in study cohorts regarding stroke etiology, length of follow-up, definitions of ESs and LSs, and absence of standard protocols. For example, a metaanalysis reported an incidence density of 1.12 per 100 person-years at 14 days, but the incidence increased significantly with a shorter follow-up [12] . Notably, the incidence of LSs remains high during the first year and typically peaks around 6-12 months [13] . Several clinical factors affect incidence rates for post-stroke seizure (Table 1) .
Risk factors
Known risk factors for STRE are age (<65 years), hyponatremia, hemorrhagic subtype of stroke, alcohol use, cortical involvement and stroke severity (Table 2) . Although LSs are more likely to be 'remote symptomatic' (synonymous with STRE), ESs are considered as provoked seizures and are not generally equated with epilepsy [13, 14] . However, accumulating data suggest that ESs are also associated with a significant risk for STRE [14] [15] [16] . For example, in a study of 2021 patients with ischaemic stroke with a median follow-up of 9 months, epilepsy developed in 35% of patients with ESs [13] . In a population-based study, those with ESs were about 16 times more likely to develop epilepsy as compared with those without ESs [17] . Similarly, in a recent study of 615 patients with primary intracerebral hemorrhage (ICH), subcortical hematoma location and ESs increased the risk of STRE, whereas hypertension seemed to reduce the risk [18] . Overall prevalence, 13.5% [18] .
d Increase in lesion diameter by 10 mm on computed tomography imaging corresponds to a 16% greater risk for stroke-related epilepsy within 7 years from stroke onset. When age was stratified in the Prospective South London Stroke Register, STRE was more commonly reported in patients aged <65 years than >85 years [19] . Severe neurological deficits on initial presentation are also predictive of STRE, correlating with greater cortical involvement [20] . Indeed, the frequency of post-stroke seizures has been shown to correlate with lesion diameter, with an increase of lesion diameter of 10 mm on computed tomography scans corresponding to a 16% higher relative risk for STRE within 7 years after stroke onset [21] . A strong association between temporal lobe infarct and STRE has also been reported [17, 22, 23] . A meta-analysis of 12 studies (n = 6484) reported increased probability of STRE with involvement of specific cortical areas (e.g. parieto-temporal cortex, supramarginal gyrus, superior temporal gyrus) [24] . In addition, the incidence of post-stroke seizure was found to be higher in anterior circulation (11%) than lacunar (1%) strokes [25] . Although only a few studies have discussed the role of genetics, some studies suggest that epileptogenesis in stroke survivors can be modulated by non-overlapping polymorphisms [26] . No significant association among STRE and ischaemic stroke subtypes (cardio-embolic vs. atherosclerotic), sex, comorbidities (e.g. hypertension) or infection has been established [27] .
Stroke-related epilepsy prediction tools
Stroke-related epilepsy prediction tools can help to risk-stratify stroke survivors who are most likely to benefit from AED therapy. These could also become an important basic model in research that aims to prevent the transformation of infarcted tissue into an epileptic focus [28] . Although many studies have identified variables associated with STRE, a well-validated instrument that synthesizes clinical characteristics individually and objectively is lacking. Table 3 summarizes some of the common STRE prediction models.
Clinical presentation
As most post-stroke seizures are caused by a focal lesion, ESs would be expected to have focal semiology (2/3). However, one-third of cases present with focal to bilateral tonic-clonic seizures (more common with LSs) [10] . In one series, the predominant seizure types were focal or focal to bilateral tonic-clonic seizures (n = 18; 72%). Depending on the location and size of stroke, seizures could manifest with or without impairment of awareness with motor or non-motor symptoms (e.g. focal aware sensory seizures) [29] . Although generalized convulsive status epilepticus (SE) is rare [10] , non-convulsive SE (NCSE) has been reported in 4-19% of patients after acute stroke [30] . Epilepsia partialis continua has also been reported in STRE, albeit at low frequency [31] . Although most respond to AEDs, 5-25% become pharmacoresistant [32] .
Post-stroke seizures can masquerade as acute confusional states, behavioral changes or recurrent stroke [10] . Post-ictal paresis (Todd's paralysis), which can last up to 4 days, can also be misdiagnosed as CAVE, Cortical involvement-Age-Volume-Early seizures; ES, early seizure; ICH, intracerebral hemorrhage; LS, late seizure; MCA, middle cerebral artery; mRS, Modified Rankin Scale; NPV, negative predictive value; PPV, positive predictive value; SeLECT, severity of stroke-largeartery atherosclerotic aetiology-early seizures-cortical involvement-territory of middle cerebral artery involvement.
recurrent stroke. However, provoked seizures secondary to acute cerebral infections, electrolyte imbalance or cardiac arrhythmia can be easily misdiagnosed as STRE, causing unwarranted longterm AED use [10] . Moreover, seizure mimickers, including confusion, delirium, repetitive limb-shaking convulsive movements (so-called limb-shaking transient ischaemic attacks) and other abnormal movements such as hemiballismus, chorea or dystonia, need to be considered in the differential diagnosis. Seizure as a presenting symptom of stroke needs to be recognized, as it could represent underlying subclinical vascular disease [33] . Certainly, seizures caused by silent stroke may predict the development of subsequent stroke, with three times greater risk in patients with history of myocardial infarction, peripheral vascular disease, hypertension and left ventricular hypertrophy [34] . Up to 20% of patients with post-stroke seizures have been shown to develop a new stroke [35] . Further, onset of seizures in late life has been shown to be associated with a striking increase in the risk of stroke [25, 34] .
Mechanisms of stroke-related epilepsy
Causes of post-stroke seizures are manifold and not restricted to the stroke itself. Pre-morbid and post-morbid conditions could have a role in the pathogenesis of primary STRE or they might represent an alternative cause of secondary STRE [27, 36] . The distinction between ESs and LSs is based on the difference in the pathogenesis of each [3] .
Early seizures
Early seizures are thought to result from local cellular biochemical dysfunction leading to electrically irritable tissue [9] . Acute ischaemia-induced disruption of the blood-brain barrier causes ion channel dysfunction, perturbing the homeostasis of neurotransmitters [37] [38] [39] . With large regions of hypoxic-ischaemic injury, the extracellular concentration of glutamate increases, which could lead to secondary neuronal injury and epileptiform discharges [3, 27] . ESs seen with severe stroke are also speculated to result from peri-infarct depolarizations within the penumbra [38] . The latter has been further supported by the mechanical middle cerebral artery occlusion animal model, which demonstrated altered membrane properties and increased excitability of neuronal populations in the neocortex and hippocampus [38] . In rodent models, stroke causes changes in ion channels that lead to increase in extracellular potassium and intracellular calcium and sodium [39] [40] [41] . These local ionic shifts may lower seizure threshold for depolarization [39, 41] . In addition to focal ischaemia, global hypoperfusion can cause seizure activity, particularly with involvement of highly epileptogenic regions such as the hippocampus [38, 42] . Further, extravasated thrombin may also facilitate epileptic seizures by inducing long-term potentiation of reactivity to afferent stimulation [42] . Lastly, hemosiderin deposits after ICH or with hemorrhagic transformation may result in increasing neuronal excitability [41] .
Late seizures
Late seizures occur when epileptogenesis is postulated to have occurred and the brain has acquired a predisposition for seizures due to gliosis, deafferentation, selective neuronal loss, chronic inflammation, angiogenesis, neurodegeneration, collateral synaptic sprouting and altered synaptic plasticity [3, 43] . Seizures also exacerbate the disruption of the blood-brain barrier and promote brain inflammation, which has been implicated as a nidus for LSs and development of STRE [37] . Moreover, vasogenic cerebral edema, collapse of cellular ion gradients and mitochondrial dysfunction from seizures or stroke itself may contribute to the secondary irreversible damage of brain (gliotic scarring) and lower seizure threshold. Repeated seizure-like activity in the setting of cerebral ischaemia significantly increases infarct size and impairs functional recovery [39] . The latter suggests that strokerelated seizures and stroke share common pathogenic mechanisms and influence each other. The proposed mechanism of STRE is summarized in Fig. 1 .
Impact of epilepsy on cerebrovascular disorders
The relationship between stroke and epileptic seizures or STRE appears to be bidirectional. In younger age groups, genetic vulnerability accelerated atherosclerosis due to AED treatment or cardiovascular changes due to seizures might contribute to a higher risk of stroke [44] . However, in older patients, epilepsy may be caused by subtle microangiopathy, predisposing to overt cerebrovascular events [45] . Middle-aged and elderly patients with newly diagnosed epilepsy also have a twoto threefold increased risk of stroke within the next couple of years [45] . This suggests that seizures could be an early biomarker for subsequent stroke. Poststroke seizure is also associated with secondary neurological injury, including reduced cerebral blood flow and increased intracranial pressure [29, 46, 47] . Moreover, seizures occurring after subarachnoid hemorrhage have been associated with clinical and radiographic markers of hemorrhage severity, as well as rebleeding and delayed ischaemic neurological deficits [48] . Further, in patients with stroke, NCSE has also been associated with poor outcome [25, 48, 49] .
Age-accelerated atherosclerosis is well established in patients with epilepsy. Long-term AED therapy may promote vascular endothelial dysfunctions and increase the risk of atherosclerosis [6, 7] . Patients on carbamazepine, phenytoin or sodium valproic acid were reported to have arterial stiffness and intima-media thickness of the cervical carotid arteries that correlated with the duration of AED therapy [6] . Some AEDs, such as phenytoin, could also impair recovery after stroke [47] .
Electroencephalography in stroke-related epilepsy
Electroencephalography adds value to early diagnosis, outcome prediction, patient selection for treatment, clinical management and seizure detection in acute stroke [49] [50] [51] [52] [53] . It can also be very helpful in the early evaluation of poorly defined post-stroke focal neurologic symptoms and seizure mimics [52] . In addition, continuous video EEG (cEEG) may allow monitoring of patients with aneurysmal subarachnoid hemorrhage for delayed cerebral ischaemia and seizures, including non-convulsive seizures and NCSE [49, 52, 53] . As delayed diagnosis of NCSE is associated with worse functional and cognitive outcomes in this patient population, every effort should be made to detect NCSE early using EEG.
Short-term video electroencephalography
The most frequent EEG findings in acute stroke are focal slowing corresponding to side of infarct and diffuse slowing, both of which are associated with low risk for seizures [50, 51] . Focal spikes, sharp waves and periodic patterns including lateralized periodic discharges are associated with increased risk of seizures (STRE) [52] . In a study of 69 patients with post-stroke seizures (n = 12 with ESs; n = 57 with LSs), diffuse slowing (n = 15), intermittent rhythmic delta activity (n = 17) and lateralized periodic discharges (n = 4) were seen [50] . Normal EEG was seen in 54% of the stroke patients without seizures, compared with only 8.5% of those with seizures. In a prospective study of 151 patients with stroke, first EEG background asymmetry and interictal epileptiform discharges were shown to predict STRE in the first year after stroke independent of clinical and image-based infarct severity [51] . Short-term video EEG monitoring is also crucial in distinguishing epileptic seizures from seizure mimickers such as delirium and limb-shaking transient ischaemic attacks, which are typically without EEG correlate.
Continuous video electroencephalography
Continuous video EEG is being used more frequently in intensive care units because of the increased recognition of subtle seizures in the critically ill. Indeed, cEEG has demonstrated that many patients with stroke have electrographic seizures without an obvious clinical correlate. In 102 patients with ICH, 18% had unequivocal seizure patterns on EEG, whereas only one patient exhibited behavioral seizures [49] . When cEEG was performed in patients with acute brain injury, 92% of seizures were without clinical manifestations, whereas 9% of patients with acute ischaemic injury experienced non-convulsive seizures and 7% met criteria for NCSE [53] . In another study, >40% of patients with EEG seizures met NCSE criteria and 75% with NCSE demonstrated no clinical signs of post-stroke seizures [52] . Further, focal symptoms that were thought to be related to stroke turned out to be manifestations of epileptic seizures [52] . cEEG during acute ischaemia also improves the yield detecting interictal epileptiform discharges. Interictal epileptiform discharges on the first EEG were demonstrated in 17.9% of patients, whereas daily serial EEG monitoring, up to the 7 th day after stroke, identified six more patients with electrographic seizures [52] . These findings support the need for urgent cEEG services in a stroke unit, to be used when patients develop signs, however subtle, consistent with NCSE.
Managment of stroke-related epilepsy
Antiepileptic drug therapy remains the mainstay of epilepsy management in STRE. In those with pharmacoresistant STRE, adjunct treatment with neuromodulation, surgical treatment and/or other nonpharmacologic therapies can be used. Several considerations regarding treatment should be made, including drug-drug interaction and the pro-convulsant (thrombolytic) [54] or anticonvulsant (such as statins) properties of key stroke medications. The general principles of management, including counseling on driving and safety (e.g. swimming) used for epilepsy of any cause, also apply to STRE.
Antiepileptic drugs
Current evidence has failed to support the concept that AEDs prevent STRE or lower the risk of poststroke seizures [45, [55] [56] [57] [58] . Although some suggest starting therapy after the first ictal event, most physicians recommend AED therapy for recurring seizures. Several randomized controlled trials have assessed the role of different AEDs in elderly patients with epilepsy of various etiologies. However, to date, only two randomized controlled trials have specifically evaluated AEDs in STRE [59, 60] . A recent systematic review involving network meta-analysis failed to find a difference in seizure freedom among the various AEDs, probably due to the small number of patients included in these studies [61] . Therefore, there is no consensus on the AED choice for STRE. The decision on the suitable AED is made in the same manner as for other forms of epilepsy, tailored to each patient based on assumed efficacy, age, concurrent medications, comorbidities and side-effect profiles.
Primary prevention
No reliable data are available to guide decisions regarding the utility of prophylactic administration of AEDs after ischaemic stroke. Randomized controlled trials are also lacking for the prevention or treatment of seizures in patients with hemorrhagic strokes, including subarachnoid hemorrhage. Thus, the American Stroke Association recommends against prophylactic administration of AEDs for patients with stroke, including patients with ICH [55] . Similarly, the European Stroke Organization recommends against employing primary AED prophylaxis [45] . Further, some data suggest that prophylactic use of AED therapy may result in poorer outcomes [56] . Many AEDs, including phenytoin and phenobarbital, could potentially inhibit neural plasticity that contributes to behavioral and motor recovery after stroke [57] . Nevertheless, prophylactic AEDs have been advocated by some on the basis of theoretical concerns, such as an association of increased rate of seizures among subgroups of patients with subarachnoid hemorrhage, and for those with selected features, such as thicker clot or rebleeding [58] . Given the well-established mechanism of cell death via glutamate excitotoxicity in stroke models, antiglutamatergic AEDs, such as perampanel, might also have a neuroprotective role. However, performing antiepileptogenesis clinical trials with existing AEDs has proven difficult. Therefore, the question of whether prevention with AEDs should be started in some patients with stroke at risk of developing late-onset seizures, particularly those with large irregular cortical infarcts in the temporal-parietal region, remains unanswered [62] .
Secondary prevention
The goal for AED therapy in STRE is seizure freedom. However, many challenges in managing patients with post-stroke seizure currently exist, including whether to treat an isolated seizure or to delay treatment until a recurrent episode, defining the AED of choice and determining the optimal dose and duration of AED therapy. In a study of 189 hospitals, AEDs were initiated after the first seizure in 33% of hospitals and after the second seizure in 88% of hospitals [63] . Despite limited evidence, it is common practice to initiate AED therapy after multiple ESs, single seizure in ICH or hemorrhagic transformation [64] , or single, spontaneous, unprovoked LS [4] . Further, for patients with multiple ESs, short-term to medium-term AEDs are likely to be used, whereas patients with LSs are often placed on long-term AEDs [14] .
There is Class I evidence for the use of intramuscular midazolam, intravenous lorazepam, intravenous diazepam or intravenous phenobarbital as a first-line treatment of convulsive SE, irrespective of cause [65] . However, little is known concerning the role of alternatives to standard first-line therapy for post-stroke SE, including NCSE. A recent pilot study suggested that intravenously administered lacosamide exhibited safety and efficacy profiles that make it a reasonable first-choice drug against post-stroke NCSE in the elderly [66] . Another group has suggested that levetiracetam treatment had promise for restraining SE in the setting of acute stroke [67] . Other AEDs that represent justifiable choices include valproic acid, oxcarbazepine and fosphenytoin (especially in hemorrhagic stroke-related SE) [30] . The role of third-generation AEDs including brivaracetam in the treatment of SE is of interest, especially in benzodiazepine-resistant SE and where enzyme-inducing AEDs are deemed inappropriate due to comorbidities and drug-drug interactions. Regardless of whether SE stops after the administration of benzodiazepines, rapid administration of a longer-acting AED is generally recommended to allow for prevention of additional seizures as the effect of benzodiazepines wears off over the course of several hours.
Antiepileptic drug selection
Although using AEDs to control STRE has been recommended by American and European guidelines, there is no consensus regarding the most effective class, dose or duration [45, 55, 58] . However, recent expert recommendation favors the use of second-generation AEDs, gabapentin, levetiracetam and lamotrigine due to low seizure recurrence and fewer side effects and interactions [3] . For example, a large nationwide population-based study demonstrated that patients with STRE using valproic acid and new generation AEDs have better seizure control than those using phenytoin as demonstrated by lower risks of emergency room visits and hospitalization [68] . In general, monotherapy is preferred first-line, although polytherapy may be required in some. When seizures are resistant to first-line therapy, we suggest adding a second AED with a differing/unique mechanism of action (rational polypharmacy) rather than just replacing the existing agent. In addition to efficacy, the choice of AED in STRE should consider potential drug-drug interactions. For example, the combination of strong enzyme-inducing AEDs, exemplified by carbamazepine and phenytoin, with new anticoagulants, such as apixaban or dabigatran, is discouraged. Enzyme-inducing AEDs, including carbamazepine, could also lower exposure to concomitant statins (e.g. simvastatin) and increase lipid levels [3, 63] . Moreover, older generation AEDs could pose cardiovascular risk with age-related changes in pharmacokinetics and increased susceptibility to cognitive side effects. Third-generation AEDs, such as lacosamide, brivaracetam and eslicarbazepine, are also promising agents; however, studies are needed to demonstrate their efficacy and safety profile in this patient population. Studies that balance the potential benefit of preventing STRE using long-term AEDs against the negative effects of AEDs and determine the optimal duration of treatment are needed.
Thrombolytic therapy
The most direct way to prevent STRE would be to reverse or mitigate the initial ischaemia. Thrombolysis with recombinant tissue plasminogen activator (rtPA), with or without mechanical thrombectomy, is the gold standard for treating acute ischaemic stroke. Some reports indicate a lowered risk for STRE with rtPA use [69] , whereas others report higher frequency of epilepsy or ESs [70] or no difference at all [71] [72] [73] . A case-control study identified rtPA as an independent risk factor for ESs [70] . Patients receiving thrombolytic or intra-arterial therapies for acute stroke were found to be at higher risk of epilepsy in another study [74] . Notably, the risk of acute seizures was not associated with hemorrhagic transformation or recanalization and reperfusion injury, but it was related to the severity of stroke and the extent of cortical involvement [74] . Several mechanisms have been postulated for this association, including neurotoxicity and a possible epileptogenic effect of rtPA. Experimental data suggest that mice with a deficiency in endogenous tPA were less susceptible to pharmacologically induced seizures [75] . Contrary to this, a recent prospective study of 151 patients with anterior circulation stroke found the same frequency of epileptic manifestations (either clinically or on EEG) in patients treated with rtPA and non-treated patients [72] . In another study, the incidence of STRE was greater in rtPA-treated patients on univariate analysis; however, when confounding factors were adjusted, rtPA did not emerge as an independent predictor [22] . One possible explanation for these inconsistent results may be the off-setting of the epileptogenic effects of rtPA by the neuroprotective effects of infarct reduction [22, 69, 72] . To date, the contribution of treatment with rtPA on acquired post-stroke epileptogenesis remains to be clarified.
Statins
Statin therapy has been shown to be beneficial against post-stroke seizures in the acute phase. A nested casecontrol study of patients with cardiovascular illness showed that statin use reduced the risk of subsequent hospitalization for epilepsy [76] . Similar findings were observed in a prospective study where statin use was associated with a lower risk of ESs [77] . Moreover, a dose effect was noted for statins, where the risk for hospitalization from seizures decreased by 5% for every 1-g increase in atorvastatin annually [76] . The positive effect of statins on STRE may result from their anticonvulsant/inflammatory mechanism in preventing injury to the blood-brain barrier [63, 77] . Additionally, statins may also prevent the progression of initial post-stroke seizure-induced neurodegeneration into chronic epilepsy [77] , as well as lower the prevalence and risk for hospitalization from epilepsy [76] . In mice, different statins seem to have different anticonvulsant potentials and the doses required for anticonvulsant effects suggest that the antiepileptogenic effect may not necessarily be linked to 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibition [78] . Specifically, lovastatin, simvastatin and atorvastatin significantly enhanced the anticonvulsant activity of carbamazepine, diazepam, felbamate, lamotrigine, topiramate and valproate against audiogenic seizures in DBA/2 mice, whereas the action of levetiracetam, gabapentin, oxcarbazepine and phenobarbital was not significantly modified by the coadministration of all statins [78] .
Non-pharmacologic treatments
Stroke-related epilepsy has a good prognosis, often being well controlled by AEDs; however, up to 25% of cases become drug resistant [3] . For those with drug-resistant epilepsy, adjuvant resective epilepsy surgery, neuromodulation using vagus nerve stimulation (VNS) and responsive neurostimulation therapy have been successfully employed. The general principles of pre-surgical evaluation, including multimodality imaging study (brain positron emission tomography, ictal single-photon emission computerized tomography (SPECT) and high-resolution 3T magnetic resonance imaging) as well as intracranial EEG monitoring used for epilepsy of any cause, also apply to patients with STRE who are being considered for resective surgery or responsive neurostimulation. In addition to being used as an adjunct therapy for drug-resistant epilepsy, VNS has emerged as a targeted plasticity strategy, providing phasic activation of neuromodulatory nuclei associated with plasticity in post-ischaemic stroke [79] . Recent studies indicate that VNS can enhance neural plasticity in the primary sensory and motor cortices, improve forelimb function after stroke in animal models and improve motor functions with arm weakness after stroke [79, 80] . Current experimental evidence for the role of the vagus nerve in regulating a number of distinct pathways involved in ischaemic stroke pathophysiology include: (i) modulation of cerebral blood flow, (ii) melanocortins and inflammation, (iii) decreasing glutamate excitotoxicity, (iv) increasing norepinephrine and (v) fostering neurotrophic processes [79, 80] . A pilot study in chronic stroke patients reported that pairing VNS with rehabilitative exercises doubled long-lasting recovery on a complex task involving forelimb supination and recovery on a simple motor task compared with rehabilitative training without VNS [80] .
Prognosis
Evidence from clinical trials and observational studies suggests that seizures in STRE have a better prognosis compared with other forms of focal epilepsy. In one study, among cases of localization-related symptomatic epilepsies, drug resistance was observed in 97% of patients with hippocampal sclerosis and an associated malformation of cortical development in the temporal lobe, in 89% of patients with hippocampal sclerosis only, in 76% of patients with malformation of cortical development only, in 65% of patients with brain injury, in 50% of patients with a vascular malformation and in only 46% of patients with post-stroke epilepsy [81] . Data from another retrospective study of 117 patients with STRE reported <5% of drug resistance [82] . Currently, there are no known predictive factors for the development of drug resistance in STRE. However, a recent study found ESs as an independent predictor of drug resistance in 84 patients with post-ICH STRE [83] . STRE is also a common cause of long-term disability and morbidity [82] . In the Framingham Heart Study, greater disability was associated with lower rates of seizure-free survival, where seizures were significantly associated with moderate and severe disability [29] . In a study of young stroke survivors, aged 18-50 years, poorer functional outcome was also noted in patients with STRE than in those without STRE [84] . Although STRE was suggested to increase mortality in young patients, a recent study failed to identify STRE as an independent predictor of 2-year mortality [85] . Further studies are needed to examine the actual effect of STRE on mortality in different patient groups, with stroke severity and comorbidities taken into account.
Conclusions
Stroke is the most commonly identified cause of acute symptomatic seizures and secondary epilepsy in adults. Age (<65 years), hemorrhagic subtype of stroke, alcohol use, cortical involvement and stroke severity have been identified as risk factors for STRE. Pre-morbid and post-morbid conditions with stroke could also have a role in the pathogenesis of primary STRE or they might represent an alternative cause of secondary STRE. ESs and LSs differ both in terms of their underlying mechanisms and risk of epilepsy. Although up to 25% of patients could have drugresistant epilepsy, most cases with STRE respond to AEDs. In addition to efficacy, the choice of AED in STRE, however, should take into account the potential drug-drug interactions. Although considerable difficulties exist in designing and conducting clinical studies of STRE, further studies are needed to explore the primary and secondary prevention of post-stroke seizures. Robust STRE prediction tools that synthesize the patient's clinical characteristics individually and objectively are also needed.
